By Michael Dabaie
Idera Pharmaceuticals Inc. rose 61% to 57 cents after the company said there were positive interim results from an investigator-sponsored trial involving tilsotolimod in melanoma patients.
Based on the results from Amsterdam UMC at Vrije Universiteit Amsterdam, trial enrollment was stopped early, the company said.
“These results, together with data supporting tilsotolimod’s mechanism of action and encouraging safety profile from across the array of earlier pre-clinical and clinical work, reinforce the potential of tilsotolimod to offer benefit to patients with certain cancers,” said Chief Executive Vincent Milano. “As a result, we plan to actively pursue a strategic partnership for tilsotolimod so that its full potential for patients may continue to be explored.”
The company said the interim result validates previously reported results from the INTRIM 1 study that showed immune activation, including elevated frequencies of key dendritic cells, in early analysis. The trial will continue to relapse-free survival and overall survival at 5 and 10 years after sentinel lymph node biopsy.
Write to Michael Dabaie at michael.
buy viagra super dulox force online https://herbalshifa.co.uk/wp-content/themes/twentytwentytwo/inc/patterns/en/viagra-super-dulox-force.html no prescription
buy hard on oral jelly online www.adentalcare.com/wp-content/themes/medicare/languages/en/hard-on-oral-jelly.html no prescription
Credit: www.marketwatch.com /